Most mRNA programs begin the same way. A coding sequence or gene of interest is selected. A codon optimization tool is run. The GC content looks acceptable. The sequence is ordered. Then expression is lower than expected, stability is inconsistent, innate immune activation appears, and manufacturing yields are unpredictable. The assumption was simple: optimize codon frequency and translation will improve. Reality is more complex. Codon optimization is only one variable in a m